Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief Medical Officer & Executive VP Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Joshua Higa - Director of Investor Relations & Corporate Communications Conference Call Participants Farzin Haque - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jack Kilgannon Allen - Robert W.
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst
Ultragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal data expected Q4 2025 could be transformative. UX111's FDA delay is manufacturing-related, not safety or efficacy; resubmission is planned, with approval possible in 2026.
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat a rare genetic disorder, the company said on Friday.
Ultragenyx shares plunge after bone disorder trial misses key interim goal
Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) slumped around 26% on Thursday afternoon after the company and partner Mereo BioPharma said their late-stage study of setrusumab in osteogenesis imperfecta failed to meet a key interim goal. Ultragenyx is developing setrusumab as a potential first-in-class treatment for osteogenesis imperfecta, a rare genetic bone disorder with no approved therapies in the US.
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
